<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02115139</url>
  </required_header>
  <id_info>
    <org_study_id>GEM 1202</org_study_id>
    <secondary_id>2013-001132-22</secondary_id>
    <nct_id>NCT02115139</nct_id>
  </id_info>
  <brief_title>GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases</brief_title>
  <acronym>GRAY-B</acronym>
  <official_title>A Multicenter, Single Arm, Phase 2 Clinical Study on the Combination of Radiation Therapy and Ipilimumab, for the Treatment of Patients With Melanoma and Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español Multidisciplinar de Melanoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Español Multidisciplinar de Melanoma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ipilimumab adds a clinical benefit to radiation therapy in patients with melanoma metastatic&#xD;
      to the brain.&#xD;
&#xD;
      Melanoma is the third most common cancer causing brain metastases, after cancers of the lung&#xD;
      and breast, which appears to reflect the relative propensity of melanoma to metastasize to&#xD;
      the central nervous system (CNS). Brain metastases are responsible for 20 to 54 percent of&#xD;
      deaths in patients with melanoma, and among those with documented brain metastases, these&#xD;
      lesions contribute to death in up to 95 percent of cases, with an estimated median overall&#xD;
      survival ranging between 1.8 and 10.5 months, depending upon other prognostic factors.&#xD;
&#xD;
      Ipilimumab is an anti-Cytotoxic T-Lymphocyte Antigen 4 (anti-CTLA4) monoclonal antibody that&#xD;
      has demonstrated a clinically relevant and statistically significant improvement in overall&#xD;
      survival, either alone (second line) or in combination with dacarbazine (DTIC) in 1st line.&#xD;
&#xD;
      Ipilimumab has shown activity against brain metastases.&#xD;
&#xD;
      According to the European Medicines Agency (EMA) approved label for Yervoy®, the use of&#xD;
      glucocorticoids at baseline (commonly prescribed when brain metastases are diagnosed) should&#xD;
      be avoided before the administration of ipilimumab. Data show that the use of even high doses&#xD;
      of glucocorticoids for the management of immune-related adverse events do not decrease the&#xD;
      efficacy of Yervoy®. There is no documented experience on the efficacy of Yervoy® when given&#xD;
      concomitantly with radiation therapy and glucocorticoids.&#xD;
&#xD;
      In experimental models, radiation therapy is synergistic to anti-Cytotoxic T-Lymphocyte&#xD;
      Antigen 4 (anti-CTLA4) strategies (abscopal effect).&#xD;
&#xD;
      There are no published results from clinical trials on the interaction between radiation&#xD;
      therapy and ipilimumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2014</start_date>
  <completion_date type="Actual">July 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year Survival Rate</measure>
    <time_frame>Expected average of 3 weeks during for the first 6 months, then every 3 months.</time_frame>
    <description>During treatment period, there will be assessments every cycle. After end of treatment every 3 month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Within 4 weeks before start treatment, week 12, 17+/-1 and every 9 + / -1 weeks until progression up to 12 months after last patient treatment initiation.</time_frame>
    <description>Median time from treatment initiation to progression of disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial PFS</measure>
    <time_frame>Within 4 weeks before start treatment, week 12, 17+/-1 and every 9 + / -1 weeks until progression up to 12 months after last patient treatment initiation.</time_frame>
    <description>median, 6-month PFS rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracranial PFS</measure>
    <time_frame>Within 4 weeks before start treatment, week 12, 17+/-1 and every 9 + / -1 weeks until progression up to 12 months after last patient treatment initiation.</time_frame>
    <description>median, 6-month PFS rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Expected average of 3 weeks during for the first 6 months, then every 3 months.</time_frame>
    <description>median value for OS estimated by kaplan meier method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Within 4 weeks before start treatment, week 12, 17+/-1 and every 9 + / -1 weeks until progression up to 12 months after last patient treatment initiation.</time_frame>
    <description>Global and Immune-related response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Rates</measure>
    <time_frame>Expected average of 3 weeks during for the first 6 months, then every 3 months.</time_frame>
    <description>Number of patients with at least one treatment-related toxicity, classified by grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Dose Delays/Reductions and Treatment Exposure.</measure>
    <time_frame>Expected average of 3 weeks during for the first 6 months, then every 3 months.</time_frame>
    <description>Treatment feasibility. Number of patients with treatment delays and reductions, categorized as function of the number of events (reductions/delays)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation of Biomarker Expression and PFS.</measure>
    <time_frame>Within 28 days before start treatment, just before the start treatment, then expected average of 3 weeks for the first 12 weeks</time_frame>
    <description>Translational study. PFS outcome reported by subgroups according to BRAF mutation status</description>
  </other_outcome>
  <other_outcome>
    <measure>Intrapatient Variation of Quantitative Apparent Diffusion Coefficients of Serial Diffusion-weighted Magnetic Resonance Imaging</measure>
    <time_frame>Baseline and 4 weeks after WBRT</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Melanoma</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles Whole-brain radiotherapy (WBRT) 30 Gy in 10 fractions (or radiobiological equivalent schedule, after Sponsor approval), starting between Cycle 1 Day 2 and Cycle 2 Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles</description>
    <arm_group_label>Ipilimumab</arm_group_label>
    <other_name>Experimental</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to give written informed consent.&#xD;
&#xD;
          2. Histologic diagnosis of melanoma.&#xD;
&#xD;
          3. First episode of radiological evidence of brain metastases&#xD;
&#xD;
          4. Be over the age of 18 years old&#xD;
&#xD;
          5. Radiation Therapy Oncology Group-recursive partitioning analysis (RTOG-RPA) class 2&#xD;
&#xD;
          6. Karnofsky performance status (PS) more than 70%&#xD;
&#xD;
          7. Barthel Index of Activities of Daily Living more than 10&#xD;
&#xD;
          8. Measurable disease (mWHO criteria).&#xD;
&#xD;
          9. Adequate organ function as determine by the following criteria:&#xD;
&#xD;
               -  White blood count (WBC) more or equal to 2000/ microliter (uL)&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) more than 1.5 x 109/L.&#xD;
&#xD;
               -  Platelet count more than 75 x 109/L.&#xD;
&#xD;
               -  Hemoglobin more than 9 g/dL. If the patient received a red blood count (RBC)&#xD;
                  transfusion, the required value of hemoglobin should be met at least 1 week after&#xD;
                  the most recent transfusion.&#xD;
&#xD;
               -  Serum creatinine less or equal to 2.0 x upper limit of normal (ULN).&#xD;
&#xD;
               -  Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT)&#xD;
                  less or equal to 2.5 x ULN for patients without liver metastasis, or less or&#xD;
                  equal to 5 times for liver metastases.&#xD;
&#xD;
               -  Total bilirubin less or equal 2.0 x ULN, (except patients with Gilbert's&#xD;
                  Syndrome, who must have a total bilirubin less than 3.0 mg/dL)&#xD;
&#xD;
         10. Persons of reproductive potential must agree to use an adequate method of&#xD;
             contraception throughout treatment and for at least 26 weeks after ipilimumab is&#xD;
             stopped&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with melanoma and brain metastases with any of the following disease-specific&#xD;
             characteristics:&#xD;
&#xD;
               -  Documented evidence of prior progression of melanoma to an ipilimumab-containing&#xD;
                  regimen (i.e. received at least 2 doses of ipilimumab for either advanced disease&#xD;
                  or in the adjuvant setting and the disease progressed/relapsed (according to mWHO&#xD;
                  criteria) within 24 weeks since the first dose of ipilimumab)&#xD;
&#xD;
               -  Prior radiation therapy to the brain&#xD;
&#xD;
               -  Other prior antineoplastic therapies for brain metastases.&#xD;
&#xD;
               -  Patients with cerebral metastases as the only location of the disease, for which&#xD;
                  local therapy (neurosurgery, radiosurgery) could achieve a disease-free status&#xD;
&#xD;
               -  Patients with a rapid clinical deterioration, or with risk of herniation, or who&#xD;
                  require unstable ascending dosing of supportive medication in the last week&#xD;
                  -including anti-convulsivants, steroids and analgesics-, or who require&#xD;
                  dexamethasone more than 16 mg/d (or other glucocorticoid at an equipotent dose),&#xD;
                  or with a high lactate dehydrogenase (LDH) more than 2 x ULN.&#xD;
&#xD;
          2. Any other malignancy form which the patient has been disease-free for less than 5&#xD;
             years, with the exception of adequately treated and cured basal or squamous cell skin&#xD;
             cancer, superficial bladder cancer or carcinoma in situ of the cervix, or incidental&#xD;
             prostate cancer.&#xD;
&#xD;
          3. Uncontrolled diabetes mellitus (HbA1c more than 9 %)&#xD;
&#xD;
          4. Autoimmune disease other than vitiligo or past thyroiditis under substitutive hormone&#xD;
             therapy: Patients with a history of inflammatory bowel disease, including ulcerative&#xD;
             colitis and Crohn's Disease, are excluded from this study, as are patients with a&#xD;
             history of symptomatic disease (eg, rheumatoid arthritis, systemic progressive&#xD;
             sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [eg,&#xD;
             Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g.&#xD;
             Guillain-Barre Syndrome and Myasthenia Gravis).&#xD;
&#xD;
          5. Other chronic intestinal diseases associated with diarrhea.&#xD;
&#xD;
          6. Active infection or other serious illness or medical condition.&#xD;
&#xD;
          7. Known active or chronic infection with HIV, Hepatitis B, or Hepatitis C.&#xD;
&#xD;
          8. Concomitant therapy with any of the following: interleukin-2 (IL-2), interferon, or&#xD;
             other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive&#xD;
             agents; other investigation therapies; or chronic use of systemic corticosteroids&#xD;
             (used for the management of non-cancer related illnesses), either concomitantly or&#xD;
             during the last 30 days prior to the beginning of the treatment.&#xD;
&#xD;
          9. Any experimental therapy administered in the past 30 days prior to the beginning of&#xD;
             the treatment.&#xD;
&#xD;
         10. Any non-oncology vaccine therapy used for the prevention of infectious diseases (for&#xD;
             up to 4 weeks prior to or after any dose of blinded study drug) (see definitions in&#xD;
             protocol text)&#xD;
&#xD;
         11. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for&#xD;
             treatment of either a psychiatric or physical (eg, infectious) illness.&#xD;
&#xD;
         12. Any other general, medical or psychological conditions which in the opinion of the&#xD;
             investigator will make the administration of ipilimumab hazardous, or that would&#xD;
             preclude appropriate informed consent or compliance with the protocol, or obscure the&#xD;
             interpretation of eventual adverse events (AEs).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José A López-Martín, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario 12 de Octubre - GEM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICO Badalona</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Insular de Canarias</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. U. Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Clínico de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. General de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 10, 2014</study_first_submitted>
  <study_first_submitted_qc>April 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2014</study_first_posted>
  <results_first_submitted>June 11, 2021</results_first_submitted>
  <results_first_submitted_qc>June 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 1, 2021</results_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>brain</keyword>
  <keyword>metastases</keyword>
  <keyword>Patients with melanoma and brain metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 28, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT02115139/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 28, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT02115139/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>58 patients were enrolled and fulfilled the inclusion criteria, analyzed for safety.&#xD;
During the trial 7 patients discontinued treatment before completion, so the total of patients for efficacy analysis was 51.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ipilimumab</title>
          <description>Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles Whole-brain radiotherapy (WBRT) 30 Gy in 10 fractions (or radiobiological equivalent schedule, after Sponsor approval), starting between Cycle 1 Day 2 and Cycle 2 Day 1&#xD;
Ipilimumab: Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>treatment discontinuation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ipilimumab</title>
          <description>Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles Whole-brain radiotherapy (WBRT) 30 Gy in 10 fractions (or radiobiological equivalent schedule, after Sponsor approval), starting between Cycle 1 Day 2 and Cycle 2 Day 1&#xD;
Ipilimumab: Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="36.8" upper_limit="84.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky performance status (KPS)</title>
          <description>Karnofsky performance status (KPS) allows patients to be classified as to their functional impairment. The scale ranges from 0 (death, worst performance) to 100 (complete functional, better performance).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>90-100</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>70-80</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not evaluable (NE)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Barthel index</title>
          <description>Barthel index measures the capacity of the person for the execution of ten basic activities in daily life. The index ranges from 0 (worst performance) to 20 (best performance).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Lower than 15</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>15-20</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BRAF mutational status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Mutated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not evaluated (NE)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of previous treatment lines</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No previous lines</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 previous line</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 or more previous lines</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of brain metastasis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Unic brain lesion</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple brain lesions</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not especified (NE)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Corticoid use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lactate dehydrogenase (LDH) blood levels</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Levels higher than Upper limit normal (ULN)</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Levels higher than 1.5X Upper limit normal (ULN)</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>1-year Survival Rate</title>
        <description>During treatment period, there will be assessments every cycle. After end of treatment every 3 month.</description>
        <time_frame>Expected average of 3 weeks during for the first 6 months, then every 3 months.</time_frame>
        <population>Efficacy cohort, all patients that fulfill eligibility and completed the treatment with radiotherapy</population>
        <group_list>
          <group group_id="O1">
            <title>Ipilimumab</title>
            <description>Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles Whole-brain radiotherapy (WBRT) 30 Gy in 10 fractions (or radiobiological equivalent schedule, after Sponsor approval), starting between Cycle 1 Day 2 and Cycle 2 Day 1&#xD;
Ipilimumab: Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>1-year Survival Rate</title>
          <description>During treatment period, there will be assessments every cycle. After end of treatment every 3 month.</description>
          <population>Efficacy cohort, all patients that fulfill eligibility and completed the treatment with radiotherapy</population>
          <units>Percentage of patients alive at 1 year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" lower_limit="18.8" upper_limit="44.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival (PFS)</title>
        <description>Median time from treatment initiation to progression of disease</description>
        <time_frame>Within 4 weeks before start treatment, week 12, 17+/-1 and every 9 + / -1 weeks until progression up to 12 months after last patient treatment initiation.</time_frame>
        <population>Efficacy population (patients that fulfill eligibility and completed the treatment with radiotherapy)</population>
        <group_list>
          <group group_id="O1">
            <title>Ipilimumab</title>
            <description>Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles Whole-brain radiotherapy (WBRT) 30 Gy in 10 fractions (or radiobiological equivalent schedule, after Sponsor approval), starting between Cycle 1 Day 2 and Cycle 2 Day 1&#xD;
Ipilimumab: Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS)</title>
          <description>Median time from treatment initiation to progression of disease</description>
          <population>Efficacy population (patients that fulfill eligibility and completed the treatment with radiotherapy)</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.11" lower_limit="2.23" upper_limit="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intracranial PFS</title>
        <description>median, 6-month PFS rate</description>
        <time_frame>Within 4 weeks before start treatment, week 12, 17+/-1 and every 9 + / -1 weeks until progression up to 12 months after last patient treatment initiation.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extracranial PFS</title>
        <description>median, 6-month PFS rate</description>
        <time_frame>Within 4 weeks before start treatment, week 12, 17+/-1 and every 9 + / -1 weeks until progression up to 12 months after last patient treatment initiation.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>median value for OS estimated by kaplan meier method</description>
        <time_frame>Expected average of 3 weeks during for the first 6 months, then every 3 months.</time_frame>
        <population>Efficacy population (patients that comply with eligibility and completed radiotherapy treatment)</population>
        <group_list>
          <group group_id="O1">
            <title>Ipilimumab</title>
            <description>Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles Whole-brain radiotherapy (WBRT) 30 Gy in 10 fractions (or radiobiological equivalent schedule, after Sponsor approval), starting between Cycle 1 Day 2 and Cycle 2 Day 1&#xD;
Ipilimumab: Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>median value for OS estimated by kaplan meier method</description>
          <population>Efficacy population (patients that comply with eligibility and completed radiotherapy treatment)</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.73" lower_limit="3.59" upper_limit="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate</title>
        <description>Global and Immune-related response criteria</description>
        <time_frame>Within 4 weeks before start treatment, week 12, 17+/-1 and every 9 + / -1 weeks until progression up to 12 months after last patient treatment initiation.</time_frame>
        <population>Efficacy population</population>
        <group_list>
          <group group_id="O1">
            <title>Ipilimumab</title>
            <description>Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles Whole-brain radiotherapy (WBRT) 30 Gy in 10 fractions (or radiobiological equivalent schedule, after Sponsor approval), starting between Cycle 1 Day 2 and Cycle 2 Day 1&#xD;
Ipilimumab: Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Global and Immune-related response criteria</description>
          <population>Efficacy population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>modified WHO criteria</title>
              <category_list>
                <category>
                  <title>Complete Response (CR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial response (PR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable disease (SD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progression disease (PD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not evaluable (NE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immun related response criteria (irRC)</title>
              <category_list>
                <category>
                  <title>Complete Response (CR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial response (PR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable disease (SD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progression disease (PD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not evaluable (NE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event Rates</title>
        <description>Number of patients with at least one treatment-related toxicity, classified by grade.</description>
        <time_frame>Expected average of 3 weeks during for the first 6 months, then every 3 months.</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Ipilimumab</title>
            <description>Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles Whole-brain radiotherapy (WBRT) 30 Gy in 10 fractions (or radiobiological equivalent schedule, after Sponsor approval), starting between Cycle 1 Day 2 and Cycle 2 Day 1&#xD;
Ipilimumab: Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event Rates</title>
          <description>Number of patients with at least one treatment-related toxicity, classified by grade.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any grade toxicity</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 or higher toxicity</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Dose Delays/Reductions and Treatment Exposure.</title>
        <description>Treatment feasibility. Number of patients with treatment delays and reductions, categorized as function of the number of events (reductions/delays)</description>
        <time_frame>Expected average of 3 weeks during for the first 6 months, then every 3 months.</time_frame>
        <population>safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Ipilimumab</title>
            <description>Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles Whole-brain radiotherapy (WBRT) 30 Gy in 10 fractions (or radiobiological equivalent schedule, after Sponsor approval), starting between Cycle 1 Day 2 and Cycle 2 Day 1&#xD;
Ipilimumab: Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Dose Delays/Reductions and Treatment Exposure.</title>
          <description>Treatment feasibility. Number of patients with treatment delays and reductions, categorized as function of the number of events (reductions/delays)</description>
          <population>safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ipilimumab delay</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ipilimumab reductions</title>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Correlation of Biomarker Expression and PFS.</title>
        <description>Translational study. PFS outcome reported by subgroups according to BRAF mutation status</description>
        <time_frame>Within 28 days before start treatment, just before the start treatment, then expected average of 3 weeks for the first 12 weeks</time_frame>
        <population>efficacy population</population>
        <group_list>
          <group group_id="O1">
            <title>Ipilimumab</title>
            <description>Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles Whole-brain radiotherapy (WBRT) 30 Gy in 10 fractions (or radiobiological equivalent schedule, after Sponsor approval), starting between Cycle 1 Day 2 and Cycle 2 Day 1&#xD;
Ipilimumab: Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Biomarker Expression and PFS.</title>
          <description>Translational study. PFS outcome reported by subgroups according to BRAF mutation status</description>
          <population>efficacy population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BRAF mutated</title>
              <category_list>
                <category>
                  <title>Progression disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No progression</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not applicable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRAF native</title>
              <category_list>
                <category>
                  <title>Progression disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No progression</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not applicable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Intrapatient Variation of Quantitative Apparent Diffusion Coefficients of Serial Diffusion-weighted Magnetic Resonance Imaging</title>
        <time_frame>Baseline and 4 weeks after WBRT</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study period, from inclusion to 30 days after treatment has ended. Approximately 1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ipilimumab</title>
          <description>Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles Whole-brain radiotherapy (WBRT) 30 Gy in 10 fractions (or radiobiological equivalent schedule, after Sponsor approval), starting between Cycle 1 Day 2 and Cycle 2 Day 1&#xD;
Ipilimumab: Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Hemianopsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Gastric Hemorrage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirrubin increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>GPT increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Testicular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pau Doñate</name_or_title>
      <organization>MFAR Clinical Research</organization>
      <email>investigacion@mfar.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

